Omeed Moaven1, Konstantinos I Votanopoulos1, Perry Shen1, Paul Mansfield2, David L Bartlett3, Greg Russell1, Richard McQuellon1, John H Stewart4, Edward A Levine5,6. 1. Department of Surgery, Wake Forest University, Winston Salem, NC, USA. 2. Department of Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA. 3. Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. 4. Department of Surgery, University of Illinois, Chicago, IL, USA. 5. Department of Surgery, Wake Forest University, Winston Salem, NC, USA. elevine@wakehealth.edu. 6. Section of Surgical Oncology, Department of General Surgery, Wake Forest Baptist Health, Winston Salem, NC, USA. elevine@wakehealth.edu.
Abstract
BACKGROUND: This study evaluated health-related quality of life (HRQOL) using patient-reported outcomes in subjects with mucinous appendiceal neoplasms who underwentcytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) as part of a randomized trial comparing mitomycin with oxaliplatin. METHODS: In this prospective multicenter study, 121 mucinous appendiceal cancer patients, with evidence of peritoneal dissemination who underwent CRS, were randomized to receive mitomycin (divided 40 mg) or oxaliplatin (200 mg/m2) for HIPEC. The Functional Assessment of Cancer Therapy Neurotoxicity (FACT-G/NTX) questionnaire was utilized to assess HRQOL. The Trial Outcome Index (TOI) is a summary index responsive to changes in physical/functional outcomes. Repeated measures mixed models with an unstructured variance matrix were applied to assess changes in HRQOL longitudinally. RESULTS:Baseline questionnaire compliance was 95.9%. Baseline physical well-being (PWB) was independently associated with overall survival (hazard ratio 0.79, 95% confidence interval 0.66-0.96; p = 0.017). The TOI was significantly lower in the mitomycin group compared with the oxaliplatin arm at 12 weeks (p = 0.044; score difference 6.35) and 24 weeks after surgery (p = 0.049; score difference 5.61). At 12 weeks after surgery, declines from baseline were significant in the TOI (p = 0.004; score decline 8.99), PWB (p < 0.001; score decline 2.83), and FWB (p < 0.001; score decline 3.42) in the mitomycin group but not the oxaliplatin group. CONCLUSIONS: Compared with mitomycin, HIPEC perfusion with oxaliplatin results in significantly better physical and functional outcomes. With similar survival outcomes and complication rates, oxaliplatin should be considered as the chemoperfusion agent of choice in mucinous appendiceal cancer patients undergoing CRS/HIPEC.
RCT Entities:
BACKGROUND: This study evaluated health-related quality of life (HRQOL) using patient-reported outcomes in subjects with mucinous appendiceal neoplasms who underwent cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) as part of a randomized trial comparing mitomycin with oxaliplatin. METHODS: In this prospective multicenter study, 121 mucinous appendiceal cancerpatients, with evidence of peritoneal dissemination who underwent CRS, were randomized to receive mitomycin (divided 40 mg) or oxaliplatin (200 mg/m2) for HIPEC. The Functional Assessment of Cancer Therapy Neurotoxicity (FACT-G/NTX) questionnaire was utilized to assess HRQOL. The Trial Outcome Index (TOI) is a summary index responsive to changes in physical/functional outcomes. Repeated measures mixed models with an unstructured variance matrix were applied to assess changes in HRQOL longitudinally. RESULTS: Baseline questionnaire compliance was 95.9%. Baseline physical well-being (PWB) was independently associated with overall survival (hazard ratio 0.79, 95% confidence interval 0.66-0.96; p = 0.017). The TOI was significantly lower in the mitomycin group compared with the oxaliplatin arm at 12 weeks (p = 0.044; score difference 6.35) and 24 weeks after surgery (p = 0.049; score difference 5.61). At 12 weeks after surgery, declines from baseline were significant in the TOI (p = 0.004; score decline 8.99), PWB (p < 0.001; score decline 2.83), and FWB (p < 0.001; score decline 3.42) in the mitomycin group but not the oxaliplatin group. CONCLUSIONS: Compared with mitomycin, HIPEC perfusion with oxaliplatin results in significantly better physical and functional outcomes. With similar survival outcomes and complication rates, oxaliplatin should be considered as the chemoperfusion agent of choice in mucinous appendiceal cancerpatients undergoing CRS/HIPEC.
Authors: Konstantinos I Votanopoulos; Greg Russell; Reese W Randle; Perry Shen; John H Stewart; Edward A Levine Journal: Ann Surg Oncol Date: 2014-10-16 Impact factor: 5.344
Authors: Chukwuemeka U Ihemelandu; Richard McQuellon; Perry Shen; John H Stewart; Konstantinos Votanopoulos; Edward A Levine Journal: Ann Surg Oncol Date: 2013-06-08 Impact factor: 5.344
Authors: Harveshp D Mogal; Edward A Levine; Greg Russell; Perry Shen; John H Stewart; Konstantinos I Votanopoulos Journal: Ann Surg Oncol Date: 2015-08-20 Impact factor: 5.344
Authors: E A Calhoun; E E Welshman; C-H Chang; J R Lurain; D A Fishman; T L Hunt; D Cella Journal: Int J Gynecol Cancer Date: 2003 Nov-Dec Impact factor: 3.437
Authors: Robin J Lurvink; Koen P Rovers; Emma C E Wassenaar; Checca Bakkers; Jacobus W A Burger; Geert-Jan M Creemers; Maartje Los; Floortje Mols; Marinus J Wiezer; Simon W Nienhuijs; Djamila Boerma; Ignace H J T de Hingh Journal: Surg Endosc Date: 2021-11-10 Impact factor: 3.453
Authors: Michel Adamina; Maxime Warlaumont; Martin D Berger; Silvio Däster; Raphaël Delaloye; Antonia Digklia; Beat Gloor; Ralph Fritsch; Dieter Koeberle; Thibaud Koessler; Kuno Lehmann; Phaedra Müller; Ralph Peterli; Frédéric Ris; Thomas Steffen; Christian Stefan Weisshaupt; Martin Hübner Journal: Cancers (Basel) Date: 2022-09-01 Impact factor: 6.575
Authors: Thamer A Bin Traiki; Sulaiman A AlShammari; Wadha S AlOtaibi; Shahad N AlAnazi; Mashal M Alnmry; Abdullah M Albdah; Noura S Alhassan Journal: Ann Med Surg (Lond) Date: 2021-06-03